Unknown

Dataset Information

0

Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy.


ABSTRACT: BACKGROUND:The role of surgical resection in the treatment of patients with metastatic/recurrent gastrointestinal stromal tumors (GIST) is unclear. The aim of this study was to identify preoperative factors associated with oncologic outcomes for recurrent/metastatic GIST after tyrosine kinase inhibitor (TKI) therapy. METHODS:We identified 107 patients with metastatic or recurrent GIST treated with TKIs and surgical resection (2002-2012). Patients that underwent palliative or incomplete resection were excluded. Complete resection was achieved in 87 patients which comprise the analytic cohort. Univariate and multivariate analyses were conducted to identify risk factors for GIST-specific survival (DSS) and time-to-recurrence (TTR). RESULTS:At a median follow-up of 51 months (91 months for survivors), median DSS was 74 months and TTR was 21 months. By univariate analysis, unifocal disease, duration of TKI?

SUBMITTER: Roland CL 

PROVIDER: S-EPMC5992050 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy.

Roland Christina L CL   Bednarski Brian K BK   Watson Kelsey K   Torres Keila E KE   Cormier Janice N JN   Wang Wei-Lien WL   Lazar Alexander J AJ   Somaiah Neeta N   Hunt Kelly K KK   Feig Barry W BW  

Journal of surgical oncology 20180215 5


<h4>Background</h4>The role of surgical resection in the treatment of patients with metastatic/recurrent gastrointestinal stromal tumors (GIST) is unclear. The aim of this study was to identify preoperative factors associated with oncologic outcomes for recurrent/metastatic GIST after tyrosine kinase inhibitor (TKI) therapy.<h4>Methods</h4>We identified 107 patients with metastatic or recurrent GIST treated with TKIs and surgical resection (2002-2012). Patients that underwent palliative or incom  ...[more]

Similar Datasets

| S-EPMC7872248 | biostudies-literature
| S-EPMC8232351 | biostudies-literature
| S-EPMC4616221 | biostudies-literature
| S-EPMC8286162 | biostudies-literature
| S-EPMC6683332 | biostudies-literature
| S-EPMC6137025 | biostudies-literature
| S-EPMC8032965 | biostudies-literature
| S-EPMC6330127 | biostudies-literature
| S-EPMC6441193 | biostudies-literature
| S-EPMC5315078 | biostudies-literature